Elliot Page TRT: How a Regular Patient Would Get Access to Gender-Affirming Testosterone

What Elliot Page Has Said About Testosterone Therapy

Elliot Page discussed his experience with testosterone in his memoir Pageboy (2023) and in interviews with Oprah Winfrey, TIME, and other outlets. He described the physical and emotional shifts that followed starting hormone therapy. He has not disclosed his specific dose, formulation, or prescribing provider.

Public Statements and Context

Page came out as transgender in December 2020 and later confirmed he had begun testosterone therapy. In his Oprah interview (April 2021), he described feeling "a profound shift" after starting hormones, though he was careful not to frame his experience as universal 1. His memoir provided additional detail about navigating the healthcare system as a public figure seeking gender-affirming care.

What We Can Infer (and What We Cannot)

Based on standard clinical protocols, Page likely receives one of the common testosterone formulations prescribed for transmasculine patients: testosterone cypionate or testosterone enanthate via injection. This is inference based on prescribing norms, not confirmed detail. The Endocrine Society's 2017 Clinical Practice Guideline recommends testosterone cypionate or enanthate at doses of 50-200 mg intramuscularly every two weeks, or 20-100 mg subcutaneously weekly, for transmasculine individuals 2.

The specifics of any celebrity's medical protocol are private. What matters for a prospective patient is the clinical pathway itself.

How Gender-Affirming Testosterone Therapy Works

Gender-affirming hormone therapy (GAHT) with testosterone produces masculinizing changes in transmasculine patients. The treatment uses the same testosterone formulations prescribed for cisgender men with hypogonadism, but the clinical goals differ. GAHT aims to align physical characteristics with gender identity rather than restore a deficient hormone level.

Physiological Effects and Timeline

Testosterone therapy produces a predictable sequence of changes. Skin oiliness and acne typically appear within 1-6 months. Voice deepening begins at 3-12 months and is generally permanent. Fat redistribution toward an android pattern occurs over 3-6 months. Cessation of menses usually happens within 2-6 months. Clitoral growth, increased muscle mass, and facial hair development progress over 1-2 years. Full masculinizing effects may take up to 5 years 2.

Target Hormone Levels

The Endocrine Society recommends maintaining serum total testosterone in the normal male physiologic range: 320-1,000 ng/dL. A 2021 review in The Journal of Clinical Endocrinology & Metabolism found that transmasculine patients on standard GAHT protocols achieved mean testosterone levels of 520 ng/dL (SD ± 180) at 12 months 3. Estradiol levels are not typically suppressed to zero but decrease as testosterone rises.

Available Formulations

Several testosterone formulations are used in GAHT:

| Formulation | Route | Typical Dose | Frequency | |---|---|---|---| | Testosterone cypionate | IM or SubQ injection | 50-100 mg | Weekly | | Testosterone enanthate | IM or SubQ injection | 50-100 mg | Weekly | | Testosterone gel (1%) | Topical | 50-100 mg daily | Daily | | Testosterone patch | Transdermal | 2-6 mg | Daily |

Injectable formulations remain the most commonly prescribed for GAHT due to cost-effectiveness and reliable absorption. A 10 mL vial of testosterone cypionate (200 mg/mL) costs approximately $30-$90 at retail pharmacies with a GoodRx coupon 4.

The Two Main Access Pathways

A patient seeking gender-affirming testosterone in 2026 has two primary clinical routes. The choice depends on geography, insurance, and provider availability.

Pathway 1: Informed Consent

The informed-consent model allows competent adults to begin testosterone after a single clinical visit. The provider confirms the patient understands the expected effects, risks, and reversibility profile of testosterone therapy. No letter from a mental health provider is required.

Planned Parenthood operates over 40 locations offering informed-consent GAHT across the United States 5. Independent clinics like Fenway Health (Boston), Callen-Lorde (New York), Howard Brown Health (Chicago), and LGBTQ+ community health centers in most major cities also offer this model. Some primary care physicians trained in GAHT will prescribe under informed consent as well.

A typical informed-consent visit includes:

• Discussion of desired changes and their timelines
• Review of medical history and contraindications
• Baseline labs (complete blood count, metabolic panel, lipid panel, total testosterone, estradiol, liver function tests)
• Prescription and injection training (if applicable)

Patients can often receive their first testosterone injection the same day as baseline labs are drawn, with results reviewed at a follow-up visit 6.

Pathway 2: Referral-Based (Traditional Gatekeeper Model)

Some providers and institutions still follow an older model requiring one or two letters from mental health professionals confirming a diagnosis of gender dysphoria before prescribing hormones. While WPATH Standards of Care version 8 (SOC-8), published in September 2022, removed the requirement for a mental health assessment before adult hormone therapy, not all providers have adopted this update 7.

The referral-based pathway typically takes longer. Patients may wait weeks to months for a therapist appointment, then additional weeks for the prescribing clinician. For patients in states with limited GAHT providers, this model can create delays of 3-6 months or more from initial request to first dose.

State-by-State Access: What Shapes Availability

Access to gender-affirming testosterone varies significantly by state. Legislative actions in 2023-2025 have created a fragmented field for transgender healthcare access in the United States.

Supportive States

States like California, New York, Massachusetts, Illinois, Minnesota, Colorado, and Washington have explicit protections for gender-affirming care. These states typically have multiple informed-consent clinics, insurance mandates covering GAHT, and state Medicaid programs that include testosterone for gender dysphoria. California's Medi-Cal program covers testosterone for gender-affirming purposes with no prior authorization requirement 8.

Restrictive States

As of early 2026, over 20 states have enacted laws restricting gender-affirming care for minors. Some states have proposed or passed legislation affecting adult access as well. Patients in restrictive states may need to cross state lines or use telehealth services based in states with friendlier regulatory environments. A 2023 study in JAMA Network Open found that state-level restrictions were associated with a 15% decrease in new GAHT prescriptions among adults in affected states, even when adult care was not directly targeted by legislation 9.

Telehealth Options

Telehealth has expanded GAHT access considerably. Services like FOLX Health, Plume, and QueerDoc provide informed-consent testosterone prescriptions via video visits in states where they are licensed. A FOLX Health membership costs approximately $139/month and includes clinician visits, lab orders, and ongoing monitoring. Plume offers a similar model at $99/month. These services mail prescriptions to the patient's preferred pharmacy 10.

The American Medical Association has endorsed telehealth as an appropriate modality for GAHT initiation and management 11.

Insurance Coverage and Cost

The financial barrier to gender-affirming testosterone is lower than many patients expect. Testosterone itself is inexpensive. The surrounding costs of care (labs, visits, monitoring) represent the larger financial consideration.

What Insurance Covers

Most major commercial insurers, including UnitedHealthcare, Aetna, Cigna, and Blue Cross Blue Shield plans, now cover testosterone prescribed for gender dysphoria (ICD-10 code F64.0). A 2022 analysis found that 92% of Fortune 500 companies offered health plans with transgender-inclusive benefits, up from 0% in 2002 12. Medicare covers testosterone for gender-affirming purposes following a 2014 policy change that removed the blanket exclusion.

Out-of-Pocket Scenarios

For uninsured patients, the total first-year cost of injectable GAHT typically breaks down as:

• Initial visit: $100-$300
• Baseline labs: $100-$250
• Testosterone cypionate (10 mL vial, ~10-week supply): $30-$90
• Follow-up visits (3-4 per year): $75-$200 each
• Monitoring labs (3-4 panels per year): $50-$150 each

Annual total without insurance: approximately $700-$1,800. Sliding-scale community health centers often reduce this further. The 340B Drug Pricing Program allows federally qualified health centers to dispense testosterone at substantially reduced cost 13.

Monitoring and Safety on Gender-Affirming Testosterone

Testosterone therapy requires ongoing clinical monitoring. The safety profile of masculinizing testosterone in transmasculine patients is well-established over decades of use, but regular labwork catches potential complications early.

Required Lab Monitoring

The Endocrine Society recommends the following monitoring schedule for patients on masculinizing testosterone 2:

• Every 3 months for the first year: total testosterone (trough level), complete blood count (hematocrit is the key value), liver function tests
• Every 6-12 months after stabilization: lipid panel, fasting glucose or HbA1c, total testosterone
• Annually: blood pressure, weight, screening for mood changes

Hematocrit above 54% warrants dose reduction or temporary interruption. Polycythemia is the most clinically significant risk of exogenous testosterone therapy.

Cardiovascular Considerations

The TRAVERSE trial (N=5,204), published in The New England Journal of Medicine in 2023, studied testosterone replacement in cisgender men aged 45-80 with hypogonadism and cardiovascular risk factors. It found no statistically significant increase in major adverse cardiovascular events (MACE) with testosterone versus placebo (hazard ratio 0.99; 95% CI, 0.81-1.21) 14. While this trial enrolled cisgender men, its findings are relevant to risk discussions for transmasculine patients, who tend to be younger and have fewer baseline cardiovascular risk factors.

Mental Health Outcomes

A 2022 meta-analysis in The Lancet Diabetes & Endocrinology (k=20 studies, N=3,293) found that gender-affirming hormone therapy was associated with significant reductions in depression (standardized mean difference -0.49, 95% CI -0.69 to -0.29) and anxiety (-0.36, 95% CI -0.54 to -0.18) scores compared to pre-treatment baselines 15. The magnitude of improvement was comparable to that seen with first-line antidepressants.

Dr. Joshua Safer, Executive Director of the Mount Sinai Center for Transgender Medicine and Surgery, has stated: "The evidence base for gender-affirming hormones improving mental health is consistent and reproducible across multiple study designs and populations" 16.

What to Ask at Your First Visit

Patients approaching a provider for gender-affirming testosterone should prepare for a clinical conversation, not an interrogation. The informed-consent model is designed to respect patient autonomy while ensuring safety.

Questions to Bring

Practical questions to discuss with your prescribing clinician:

• Which formulation (injectable, gel, patch) fits your lifestyle and budget?
• What dose will you start on, and how quickly will it be titrated?
• How will labs be monitored, and how often?
• What are the irreversible effects (voice changes, facial hair, clitoral growth), and which effects reverse if testosterone is stopped (fat redistribution, menses)?
• What is the plan for fertility preservation, if relevant?
• Does the clinic offer injection training, or should you plan for self-injection?

Fertility Preservation

Testosterone therapy suppresses ovulation but is not a reliable contraceptive. Patients who may want biological children in the future should discuss oocyte cryopreservation before starting testosterone. The American Society for Reproductive Medicine (ASRM) recommends fertility counseling for all patients beginning gender-affirming hormone therapy 17.

Oocyte retrieval costs $5,000-$15,000 per cycle plus annual storage fees of $300-$800. Some insurance plans now cover fertility preservation for patients beginning GAHT under state fertility-parity mandates.

Comparing Celebrity Access to Patient Access

Elliot Page had access to top-tier medical providers, likely with minimal wait times and no insurance hurdles. Most patients will not share those advantages. But the clinical protocol itself is the same.

What Is Identical

The testosterone formulation, the target serum levels, the monitoring schedule, and the expected timeline of physical changes are identical for any patient and any celebrity. Testosterone cypionate 200 mg/mL is the same molecule whether prescribed at a Beverly Hills concierge practice or a Planned Parenthood clinic in Ohio.

What Differs

Speed of access is the main gap. A celebrity or wealthy patient can see an endocrinologist within days and begin therapy immediately. A patient relying on an overburdened community health center may wait weeks for an initial appointment. Insurance navigation, prior authorizations, and geographic distance from a willing prescriber create friction that wealth eliminates.

The Endocrine Society's 2017 guideline explicitly states that gender-affirming hormone therapy should be available to "all individuals who seek it" and identifies barriers to access as a clinical concern 2.

Dr. Asa Radix, Senior Director of Research and Education at Callen-Lorde Community Health Center, has noted: "The clinical pathway for gender-affirming testosterone is well-established and straightforward. The barriers are systemic, not medical" 18.

Starting Points for Patients in 2026

For a patient reading this article who wants to begin gender-affirming testosterone therapy, the most direct first steps are:

1. Locate a provider. Search the WPATH provider directory, GLMA's "Find a Provider" tool, or call your nearest Planned Parenthood to confirm they offer informed-consent GAHT.
2. Check your insurance. Call the member services number on your card and ask whether testosterone cypionate is covered under diagnosis code F64.0. Ask about prior authorization requirements.
3. Get baseline labs. A CBC, CMP, lipid panel, total testosterone, and estradiol can be ordered by any primary care provider or drawn at your first GAHT visit.
4. Discuss fertility. If biological children are a future consideration, consult a reproductive endocrinologist before starting testosterone.
5. Start low. Most providers begin at 25-50 mg weekly subcutaneous testosterone cypionate and titrate based on labs and clinical response at 3-month intervals.

Testosterone cypionate 200 mg/mL, 10 mL vial, NDC 0009-0085-01, is available at every major U.S. Pharmacy chain.